Welcome to the 2019 Fall Issue of the Health Advisory Council Newsletter. NCL and Council Members have been active on many fronts. Please read our Policy updates, Member updates, and new Council Member introductions.
NCL health policy at work
NCL continues to have a strong focus on counterfeit drugs, both in the policy arena and with consumer education. We issued a warning against the White House announcement to open a pathway for importation of drugs from outside of the United States. The unworkable proposal not only poses safety and purity challenges, but without requiring any potential cost-savings to be passed on to the consumer, there are no guarantees that it will save consumers money.
New NCL staff spotlight
Get to know NCL’s new Director of Health Policy, Patricia Kelmar, JD, with a new Q&A.
Please join us in welcoming the Health Advisory Council’s newest members, AbbVie, FDA MedWatch, and Greenwich Biosciences! Learn more about them here.
Get the latest updates on programs, policy, and initiatives from our Members, including AMAG, BeMedWise, CDC, CHPA, and many more.
We want to hear from you!
If you have time-sensitive information and updates you’d like to share with the Health Advisory Council in between NCL’s quarterly newsletters, please contact Nissa Shaffi (email@example.com), and we will be happy to forward your materials to the Council membership. We also encourage you to contact us with your ideas and suggestions for Council activities.
National Consumers League
Health Advisory Council Newsletter | Fall 2019
Published October 24, 2019